Skip to content

Citalopramin preventing depression in moderate TBI

The effectiveness of Citalopramin preventing depression in patients with moderate Traumatic brain injury

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221108056446N9
Enrollment
300
Registered
2024-08-07
Start date
2024-09-22
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate brain trauma. S06.2

Interventions

Intervention 1: Intervention group: Patients in the citalopram intervention group were prescribed 10 mg per day for the first 3 days, then increased to 20 mg per day. Intervention 2: Control group: Th

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with a consciousness coefficient between 9 and 13 Conscious consent of first -degree companions to enter the study Complete recovery from trauma 4 weeks after the incident Patients with a history of mood disorder must be in complete remission for at least 1 year after discontinuation of treatment

Exclusion criteria

Exclusion criteria: Patients with persistent depression or any other mood disorder based on medical records and doctor's definitive diagnosis Pregnant women or women who plan to become pregnant during the study period Previous history of allergy to Citalopramin Complex and debilitating underlying disease such as cancer, advanced heart failure

Design outcomes

Primary

MeasureTime frame
Prevention of depression. Timepoint: One, three and 6 months after the injury. Method of measurement: Glasgow coma scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Shafiei

Esfahan University of Medical Sciences

mui@mui.ac.ir+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026